[Skip to Content]
[Skip to Content Landing]
Viewpoint
May 23/30, 2017

FDA Approval of Desmopressin for Nocturia

Author Affiliations
  • 1Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts
  • 2University of Toronto Clinician-Scientist Program, Toronto, Ontario, Canada
JAMA. 2017;317(20):2059-2060. doi:10.1001/jama.2017.4316

On March 3, 2017, the US Food and Drug Administration (FDA) approved desmopressin nasal spray (Noctiva) for the “treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void.”1 According to the product manufacturer, Serenity Pharmaceuticals, nocturia is a common condition affecting “over 89 million adults in the U.S.”2

First Page Preview View Large
First page PDF preview
First page PDF preview
×